Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Randomized, Double Blind, Placebo Controlled, Dose-Escalation and -Expansion Study to Evaluate the Safety, Tolerability, PK, and PD of Subcutaneously Administered SRSD216 in Patients With Elevated Lipoprotein(a)

NCT07172646 is registered in ClinicalTrials.gov with Sirius Therapeutics Co., Ltd. as lead sponsor.

NCT NCT07172646
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07172646 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Randomized, Double Blind, Placebo Controlled, Dose-Escalation and -Expansion Study to Evaluate the Safety, Tolerability, PK, and PD of Subcutaneously Administered SRSD216 in Patients With Elevated Lipoprotein(a)
Lead sponsor
Sirius Therapeutics Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 7, 2025
Completion date
April 30, 2027
Enrollment
84 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hyperlipoproteinemia (a)